Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 18/20 | 0.76 |
| ▸ | KDR | P35968 | 18/20 | 0.76 |
| ▸ | MET | P08581 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1873999 | 0.96 | PDGFRA (0.70) | PDGFRAKDRMET | |
| SCHEMBL6863060 | 0.89 | PDGFRA (0.60) | PDGFRAKDRMET | |
| SCHEMBL29973354 | 0.89 | PDGFRA (0.95) | PDGFRAKDR | |
| SCHEMBL27081475 | 0.89 | PDGFRA (0.95) | PDGFRAKDR | |
| SCHEMBL1874002 | 0.88 | PDGFRA (0.59) | PDGFRAKDRMET | |
| SCHEMBL7480693 | 0.88 | PDGFRA (0.82) | PDGFRAKDR | |
| SCHEMBL3931065 | 0.86 | PDGFRA (1.00) | PDGFRAKDR | |
| SCHEMBL7482808 | 0.84 | PDGFRA (0.87) | PDGFRAKDR | |
| SCHEMBL7490931 | 0.84 | PDGFRA (1.00) | PDGFRAKDR | |
| SCHEMBL7489320 | 0.84 | PDGFRA (0.87) | PDGFRAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242603-A1 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-12-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242603-A1 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same | NR1H2, NR1H3, NR1H4 | PDGFRA 1364/4885KDR 1874/4885MET 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.